ABOUT RECELL® SYSTEM IN THE UNITED STATES

Small Virus

THE RECELL® SYSTEM

AVITA Medical’s first product, the RECELL® System, is a device that enables healthcare professionals to produce a suspension of Spray-On Skin™ Cells using a small sample of the patient’s own skin. This suspension contains the cells necessary to regenerate the outer layer of natural, healthy skin and is prepared and applied at the point-of-care in as little as 30 minutes.

New

SCIENTIFIC AND CLINICAL EVIDENCE

New

SCIENTIFIC AND CLINICAL EVIDENCE

The RECELL® System isolates skin cells from a small skin sample to produce Spray-On Skin™ Cells. The regenerative cell suspension includes keratinocytes, fibroblasts, and melanocytes, which play a critical role in wound healing.

LEARN MORE
Chest

Point-of-Care Regenerative Medicine

Chest

Point-of-Care Regenerative Medicine

Skin Regeneration Transformed

RECELL® is a revolutionary approach to overcome limitations associated with traditional autografting techniques with proven clinical results.

LEARN MORE

RECELL® CASE STUDIES

${treatment.title}

${image.caption}

${image.caption}

LEARN MORE

AVITA MEDICAL: INNOVATORS IN REGENERATIVE MEDICINE AROUND THE WORLD

EUROPE USA AUSTRALIA

RECELL® is FDA approved in the USA for the treatment of acute thermal burn wounds in patients 18 years of age and over, TGA-registered in Australia, CE-marked in Europe.

RECELL® is FDA approved in the USA for the treatment of acute thermal burn wounds in patients 18 years of age and over, TGA-registered in Australia, CE-marked in Europe.

Join Our Community

Be the first to receive news, updates, and event information from AVITA Medical.

CONTACT US

IMPORTANT SAFETY INFORMATION

INDICATIONS FOR USE: The RECELL® Autologous Cell Harvesting Device is indicated for the treatment of acute thermal burn wounds in patients 18 years of age and older. The RECELL® device is used by an appropriately-licensed healthcare professional at the patient’s point of care to prepare autologous Regenerative Epidermal Suspension (RES™) for direct application to acute partial-thickness thermal burn wounds or application in combination with meshed autografting for acute full-thickness thermal burn wounds.

CONTRAINDICATIONS: RECELL® is contraindicated for the treatment of wounds clinically diagnosed as infected or with necrotic tissue present in the wound bed. RECELL® is contraindicated for the treatment of patients with a known hypersensitivity to trypsin or compound sodium lactate solution (Hartmann’s Solution). The skin sample collection procedure specified for use of RECELL® should not be used with patients having a known hypersensitivity to anesthetics, adrenaline/epinephrine, povidone-iodine, or chlorhexidine solutions.

WARNINGS: Autologous use only. Wound beds treated with a cytotoxic agent (e.g., silver sulfadiazine) should be rinsed prior to application of the cell suspension. RECELL® is provided sterile and is intended for single-use. Do not use RECELL® or device components if packaging is damaged, there are signs of tampering or date of use is beyond the stated expiration date. Choose a skin sample donor site that shows no evidence of surrounding cellulitis or infection. The skin sample should be processed immediately after harvesting. If a skin sample is harvested and processed according to these instructions, it should require between 15 and 30 minutes of contact with the Enzyme. Contact in excess of 60 minutes is not recommended. RECELL® Enzyme is animal derived and manufactured under strict controls to minimize risk of contamination, freedom from infectious agents cannot be guaranteed.

PRECAUTIONS: RECELL® is not intended to be used alone (i.e., without meshed autograft) for treatment of full-thickness burn wounds. The safety and effectiveness of RECELL® used alone (i.e., without meshed autograft) have not been established for treatment of partial-thickness burn wounds: on the hands and articulated joints, >320 cm2, in patients with wounds totaling >20% Total Body Surface Area (TBSA). The safety and effectiveness of RECELL® plus autografting have not been established for treatment of full-thickness burn wounds: on the hands and articulated joints, in patients with wounds totaling >50% Total Body Surface Area (TBSA).

SPECIAL PATIENT POPULATIONS: The safety and effectiveness of RECELL® have not been established for treatment of acute thermal partial-thickness or full-thickness burn wounds in pediatric patients younger than 18 years of age.

For complete Important Safety Information, refer to Instructions For Use.

This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our privacy policy.